Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

VYNE Therapeutics (VYNE) Cash from Operations (2017 - 2025)

VYNE Therapeutics (VYNE) has disclosed Cash from Operations for 9 consecutive years, with 10803000.0 as the latest value for Q2 2025.

  • For the quarter ending Q2 2025, Cash from Operations fell 27.36% year-over-year to 10803000.0, compared with a TTM value of 39773000.0 through Jun 2025, down 48.67%, and an annual FY2025 reading of 33124000.0, up 2.5% over the prior year.
  • Cash from Operations was 10803000.0 for Q2 2025 at VYNE Therapeutics, up from 11461000.0 in the prior quarter.
  • Across five years, Cash from Operations topped out at 4811000.0 in Q4 2022 and bottomed at 17541000.0 in Q3 2021.
  • Average Cash from Operations over 5 years is 9285777.78, with a median of 8754500.0 recorded in 2024.
  • The sharpest move saw Cash from Operations soared 75.96% in 2021, then crashed 75.18% in 2024.
  • Year by year, Cash from Operations stood at 10018000.0 in 2021, then surged by 51.98% to 4811000.0 in 2022, then decreased by 6.78% to 5137000.0 in 2023, then tumbled by 75.18% to 8999000.0 in 2024, then decreased by 20.05% to 10803000.0 in 2025.
  • Business Quant data shows Cash from Operations for VYNE at 10803000.0 in Q2 2025, 11461000.0 in Q1 2025, and 8999000.0 in Q4 2024.